The best clinical paper on multiple sclerosis in 2014: Herodotus and Chataway − Commentary

Abstract

Get full access to this article

View all access options for this article.

References

Holland

. Herodotus. The histories (translated by Holland

Tom

). London: Penguin, 2013, pp.193–194.

Simon

Munger

Ascherio

. Vitamin D and multiple sclerosis: Epidemiology, immunology, and genetics. Curr Opin Neurol 2012; 25: 246–251.

Ascherio

Munger

White

. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014; 71: 306–314.

Smolders

Hupperts

Barkhof

. SOLAR study group. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci 2011; 311: 44–49.

Dorr

Ohlraun

Skarabis

. Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): Study protocol for a randomized controlled trial. Trials 2012; 13: 15.

Stein

Liu

Gray

. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011; 77: 1611–1618.

Chataway

Schuerer

Alsanousi

. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebo-controlled, phase 2 trial. The Lancet 2014; 383(9936): 2213–2221.